Table 1:
Intravenous C57BL/6, BALB/c and A/J mouse models of disseminated candidiasis.
| Candida strain | Challenge dose1 | Mouse strain |
|---|---|---|
| C. albicans SC5314 (ATCC MYA-2876) | 2×106/5×105 | C57BL/6 / BALB/c |
| C. tropicalis (ATCC200956) 2 | 1×108 | C57BL/6; A/J; BALB/c (CY i.p. treatment) |
| C. glabrata (ATCC 200918) 3 | 1 ×108 | C57BL/6 & BALB/c (CY2 by i.p. weekly + cortisone by s.c. daily) |
| C. glabrata (ATCC 200918) | 1×108 | A/J (CY i.p. treatment) |
| C. auris (AR-CDC 0386) | 2×108 | A/J; C57BL/6 & BALB/c (CY i.p. treatment), |
| C. parapsilosis ATCC22019 | 1×107 | C57BL/6 & BALB/c (CY i.p. treatment) |
1
The optimal doses of each Candida strain for producing an acute infection with 60–100% of animals dying within 10–20 days in C57BL/6, BALB/c and A/J mouse strains
2
C. tropicalis (ATCC200956); amphotericin B-resistant
3
C. glabrata (ATCC 200918); fluconazole-resistant